Pharmaceutical composition as well as preparation method and application thereof

A composition and drug technology, applied in the directions of drug combination, drug delivery, pharmaceutical formulation, etc., can solve the problems of inability to fully exert sustained release, affect drug efficacy, and short sustained release time, and achieve the goal of facilitating intra-articular injection. drug, delaying the rate of biodegradation, and maintaining the balance of bone homeostasis

Pending Publication Date: 2022-03-22
SHANDONG UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In order to solve the problems in the prior art that the structure of the anti-inflammatory drug is complex, the drug is easily affected by the addition of the carrier, and the slow-release time is short, so that the slow-release effect cannot be fully exerted, the present invention proposes a pharmaceutical composition and its Preparation method and application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition as well as preparation method and application thereof
  • Pharmaceutical composition as well as preparation method and application thereof
  • Pharmaceutical composition as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0031] The second aspect of the present invention provides a preparation method of a pharmaceutical composition, comprising: dissolving the release-controlling polymer in water, stirring to form a gel, and then adding interleukin-10.

[0032] In one or more embodiments of the present invention, the mass fraction of hyaluronic acid is 0.1-5%, preferably 2%; the concentration of interleukin-10 is 0.1-200 μg / mL, preferably 100 μg / mL.

[0033] The stirring temperature is 4-20° C., and the stirring time is 10-15 hours.

[0034] The third aspect of the present invention provides the application of a pharmaceutical composition in the preparation of medicines for treating IL-10-mediated diseases.

[0035] In one or more embodiments of the present invention, the IL-10-mediated disease is joint inflammatory disease.

[0036] In one or more embodiments of the present invention, the joint inflammatory disease is selected from rheumatoid arthritis, osteoarthritis and other inflammatory di...

Embodiment 1

[0040] Preparation and characterization of interleukin-10 combined with hyaluronic acid hydrogel system

[0041] (1) An appropriate amount of hyaluronic acid was dissolved in distilled water, the mass fraction of hyaluronic acid was 2%, and stirred at a low temperature of 10° C. for 12 hours to obtain a modified hyaluronic acid hydrogel.

[0042] (2) Add interleukin-10 to the above-mentioned hyaluronic acid hydrogel and mix thoroughly at 250 rpm for 40 minutes, wherein the concentration of interleukin-10 is 100 μg / mL to obtain a hyaluronic acid hydrogel system loaded with interleukin-10. Prepared products such as figure 1 shown.

Embodiment 2

[0044] Application of interleukin-10 combined with hyaluronic acid hydrogel system in the treatment of osteoarthritis

[0045] (1) Grouping of experimental animals: 15 rats were randomly divided into 5 as blank control group, and the remaining 10 rats were intra-articularly injected with sodium iodoacetate to construct an osteoarthritis model. Among the 10 model mice, 5 were randomly selected as the drug treatment group for intra-articular drug administration.

[0046] (2) Construction of animal model: 1% pentobarbital sodium intraperitoneal injection (40mg / kg) for anesthesia, skin preparation at the knee joint of rats in a sterile environment, iodophor disinfection, and sodium iodoacetate drawn with a micro-syringe The solution was injected into the knee joint cavity, and the injection dose for each rat was 3 mg (50 μL). The blank control group received no other treatment.

[0047] (3) Administration method:

[0048] The first group (blank control group): normal feeding. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of pharmaceutical compositions, in particular to a pharmaceutical composition as well as a preparation method and application thereof, and more particularly relates to a pharmaceutical composition for preventing or treating inflammatory diseases as well as a preparation method and application thereof. In order to solve the problems that in the prior art, an anti-inflammatory drug is complex in structure, the drug effect of the drug is easily influenced after a carrier is added, the slow release time is short, and the slow release effect cannot be fully played, the invention provides a pharmaceutical composition as well as a preparation method and application thereof. The controlled-release polymer and the interleukin-10 are combined to prepare the pharmaceutical composition for the first time, and experiments find that the combination of the interleukin-10 and the specific controlled-release polymer can effectively relieve the damage of articular cartilage of an osteoarthritis model rat and inhibit the disease progress of osteoarthritis.

Description

technical field [0001] The present invention relates to the field of pharmaceutical compositions, in particular to a pharmaceutical composition and its preparation method and application, more specifically to a pharmaceutical composition for preventing or treating inflammatory diseases, its preparation method and application. Background technique [0002] The information disclosed in this background section is only intended to increase the understanding of the general background of the present invention, and is not necessarily taken as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to those skilled in the art. [0003] Osteoarthritis (OA) is the most common degenerative joint disease, which is caused by the complex interaction of genetic, metabolic, biochemical and biomechanical factors causing damage to articular cartilage. [0004] The current clinical strategies for the treatment of osteoarthritis mainly include no...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/20A61K47/36A61K9/06A61P19/02A61P29/00A61P31/00A61P19/04
CPCA61K38/2066A61K47/36A61K9/06A61K9/0024A61P19/02A61P29/00A61P31/00A61P19/04
Inventor 张元凯杨辉荆卫强王甘雨崔智伟刘志鑫
Owner SHANDONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap